100% and 80% ORRs in Subset Indications in azer-cel study
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The study indicates strong clinical interest, with faster enrolment in the CAR T-naïve cohort compared to previous cohorts. The company is also amending the study protocol to evaluate azer-cel in combination with Bruton Tyrosine Kinase inhibitors. Imugene aims to prioritize indications showing the strongest clinical activity as it continues patient enrolment across multiple sites.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Imugene
- Trading Halt
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- FDA Supports Strategy Toward Registration for Azer-cel
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Later from Imugene
- $20M placement and SPP, convertible notes amended
- Prospectus
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- First Patient in BTKi Combination Cohort of azer-cel study
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene